Hana Pharm Co Ltd

Hana Pharm Co Ltd has a market price of 9,630 KRW and a market cap of 169,483,050,180 KRW, with a price-to-earnings ratio of 19.31 and a price-to-book ratio of 0.54. The company's liquidity position is characterized by a current ratio of 1.84, indicating a moderate ability to meet short-term obligations. However, the company has negative net cash after subtracting total debt, which is a key liquidity flag. In terms of profitability, Hana Pharm Co Ltd has a return on equity (ROE) of 2.8% and a return on assets (ROA) of 2.1%. These figures are below the typical thresholds for strong performance in the pharmaceutical industry, suggesting that the company is not generating returns at a level that outperforms its peers. The company's operating margin is 10.7%, calculated from its operating income of 25,738,698,220 KRW and revenue of 239,503,892,660 KRW, which is in line with the industry median. Hana Pharm Co Ltd's revenue is concentrated in a single business segment, as disclosed in its financial statements. The company does not provide detailed geographic revenue breakdowns, but it is primarily focused on the Korean market. This concentration may expose the company to regional economic and regulatory risks. The company's growth trajectory is modest, with no significant revenue growth reported in the latest financial period. The company's capital expenditures were -31,182,001,790 KRW, indicating a reduction in investment in physical assets. This may suggest a strategic shift or a focus on cost optimization rather than expansion. The risk assessment for Hana Pharm Co Ltd indicates a medium liquidity risk and a low dilution risk. The company's debt-to-equity ratio is 0.19, which is relatively low, but the negative net cash position is a concern. The company has not issued new shares recently, and there is no indication of dilution pressure in the near term. Recent events and filings do not indicate any major changes in the company's operations or strategy. The company's financial statements show a consistent pattern of operations, with no significant one-time events or restructuring activities reported. The company's free cash flow is negative, which may limit its ability to fund new initiatives or return value to shareholders.